#ACImmune announces positive interim results from a Phase 1 study of ACI-19764 – its wholly-owned #NLRP3 #inflammasomeinhibitor targeting #chronicinflammation across #inflammatory, #metabolic, and #neurologicaldiseases.
pharmaphorum.com/news/positiv...
pharmaphorum.com/news/positiv...
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor
AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.
pharmaphorum.com
August 21, 2026 at 11:37 AM
#ACImmune announces positive interim results from a Phase 1 study of ACI-19764 – its wholly-owned #NLRP3 #inflammasomeinhibitor targeting #chronicinflammation across #inflammatory, #metabolic, and #neurologicaldiseases.
pharmaphorum.com/news/positiv...
pharmaphorum.com/news/positiv...
Und gleich hinterher eine Aktienplatzierung zu 3,50 Dollar mit etwa 50 Millionen Dollar Volumen. Killt leider etwas das gerade entstandene Momentum beim Aktienkurs. Mal gespannt was im "regulären" Nasdaq-Handel passiert... ir.acimmune.com/news-release... #acimmune $ACIU
December 15, 2023 at 1:14 PM
Und gleich hinterher eine Aktienplatzierung zu 3,50 Dollar mit etwa 50 Millionen Dollar Volumen. Killt leider etwas das gerade entstandene Momentum beim Aktienkurs. Mal gespannt was im "regulären" Nasdaq-Handel passiert... ir.acimmune.com/news-release... #acimmune $ACIU
Interessanter Meilenstein für #ACImmune $ACIU bei #Alzheimer mit vielen Millionen von #Janssen ... ir.acimmune.com/news-release...
December 15, 2023 at 12:43 PM
Interessanter Meilenstein für #ACImmune $ACIU bei #Alzheimer mit vielen Millionen von #Janssen ... ir.acimmune.com/news-release...
#ACImmune #AlzheimersDisease #Tautargetingtherapy #Alzheimerstrial #ACI35030 #Tautargetingactiveimmunotherapy #immunotherapy #earlyAlzheimersdisease #SupraAntigentechnology #JACI35054 #polyclonalantibody #Tau #phosphorylatedTau #pTau #brainderivedTau #ePHF #ReTaintrial
zurl.co/MY6hl
zurl.co/MY6hl
AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial - PharmaTimes
Early-stage study reveals strong immune response and safety profile for ACI-35.030
pharmatimes.com
October 1, 2025 at 11:43 AM
Swiss biotech #ACImmune has said that its vaccine-like alpha-synuclein-targeted #immunotherapy has shown promise in slowing down the progression of #Parkinsonsdisease.
AC Immune says Parkinson's drug slows progression
AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.
buff.ly
December 11, 2025 at 4:00 PM
Swiss biotech #ACImmune has said that its vaccine-like alpha-synuclein-targeted #immunotherapy has shown promise in slowing down the progression of #Parkinsonsdisease.
(NASDAQ: #ACIU)
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...
September 4, 2025 at 6:24 PM
(NASDAQ: #ACIU)
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...